Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD

Nature Reviews Nephrology

Volumn 12, Issue 1, 2016, Pages 5-6

  Chan, Henry Lik Yuen ^a   Li, Philip Kam Tao ^b  

^a Institute of Digestive Disease   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE;

ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; HEPATITIS C; HUMAN; KIDNEY; PRIORITY JOURNAL; SEROCONVERSION; SHORT SURVEY; FEMALE; HEPATITIS C, CHRONIC; MALE; RENAL INSUFFICIENCY, CHRONIC;

BENZOFURANS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; PROTEASE INHIBITORS; QUINOXALINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84951907041     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.189     Document Type: Short Survey

References (10)

1. Li, P. K., Chow, K. M. Infectious complications in dialysis-epidemiology and outcomes. Nat. Rev. Nephrol. 8, 77-88 (2011).
2. Fabrizi, F. et al. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J. Viral Hepat. 21, 681-689 (2014).
3. Roth, D. et al. Grazoprevir-elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 17-23 (2015).
4. Webster, D. P. et al. Hepatitis C. Lancet 385, 1124-1135 (2015).
5. Saxena, V. et al. SLP08: Safety and efficacy of Sofosbuvir-containing regimes in HCV infected patients with reduced renal function: real-world experience from HCV-TARGET. J. Hepatol. 62, S267 (2015).
6. Ferenci, P. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983-1992 (2014).
7. Pockros, P. et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabusvir for treatment HCV genotype 1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 Study. J. Hepatol. 62, S257 (2015).
8. Zeuzem, S. et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patient with chronic HCV genotype 1, 4 and 6 infection: a randomized trial. Ann. Intern. Med. 163, 1-13 (2015).
9. Fabrizi, F. et al. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality J. Viral Hepat. 19, 601-607 (2012).
10. International Society of Nephrology. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 109, S1-S99 (2008).